SQURPHARMA Statistics
Total Valuation
Square Pharmaceuticals PLC. has a market cap or net worth of BDT 199.36 billion. The enterprise value is 143.19 billion.
Market Cap | 199.36B |
Enterprise Value | 143.19B |
Important Dates
The last earnings date was Wednesday, October 23, 2024.
Earnings Date | Oct 23, 2024 |
Ex-Dividend Date | Nov 24, 2024 |
Share Statistics
Square Pharmaceuticals PLC. has 886.45 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 886.45M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | +0.11% |
Owned by Insiders (%) | 35.18% |
Owned by Institutions (%) | 4.31% |
Float | 574.64M |
Valuation Ratios
The trailing PE ratio is 9.85 and the forward PE ratio is 9.49.
PE Ratio | 9.85 |
Forward PE | 9.49 |
PS Ratio | 2.90 |
PB Ratio | 1.64 |
P/TBV Ratio | n/a |
P/FCF Ratio | 19.28 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.21, with an EV/FCF ratio of 13.85.
EV / Earnings | 7.08 |
EV / Sales | 2.08 |
EV / EBITDA | 6.21 |
EV / EBIT | 7.07 |
EV / FCF | 13.85 |
Financial Position
The company has a current ratio of 14.39, with a Debt / Equity ratio of 0.01.
Current Ratio | 14.39 |
Quick Ratio | 11.19 |
Debt / Equity | 0.01 |
Debt / EBITDA | 0.08 |
Debt / FCF | 0.15 |
Interest Coverage | 82.28 |
Financial Efficiency
Return on equity (ROE) is 17.52% and return on invested capital (ROIC) is 9.41%.
Return on Equity (ROE) | 17.52% |
Return on Assets (ROA) | 8.99% |
Return on Capital (ROIC) | 9.41% |
Revenue Per Employee | 5.50M |
Profits Per Employee | 1.62M |
Employee Count | 12,503 |
Asset Turnover | 0.56 |
Inventory Turnover | 2.93 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.15% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +7.15% |
50-Day Moving Average | 225.50 |
200-Day Moving Average | 217.74 |
Relative Strength Index (RSI) | 57.59 |
Average Volume (20 Days) | 395,293 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Square Pharmaceuticals PLC. had revenue of BDT 68.81 billion and earned 20.24 billion in profits. Earnings per share was 22.83.
Revenue | 68.81B |
Gross Profit | 33.21B |
Operating Income | 17.66B |
Pretax Income | 24.40B |
Net Income | 20.24B |
EBITDA | 20.46B |
EBIT | 17.66B |
Earnings Per Share (EPS) | 22.83 |
Balance Sheet
The company has 48.40 billion in cash and 1.55 billion in debt, giving a net cash position of 56.17 billion or 63.37 per share.
Cash & Cash Equivalents | 48.40B |
Total Debt | 1.55B |
Net Cash | 56.17B |
Net Cash Per Share | 63.37 |
Equity (Book Value) | 121.79B |
Book Value Per Share | 137.39 |
Working Capital | 63.33B |
Cash Flow
In the last 12 months, operating cash flow was 14.19 billion and capital expenditures -3.85 billion, giving a free cash flow of 10.34 billion.
Operating Cash Flow | 14.19B |
Capital Expenditures | -3.85B |
Free Cash Flow | 10.34B |
FCF Per Share | 11.66 |
Margins
Gross margin is 48.27%, with operating and profit margins of 25.67% and 29.41%.
Gross Margin | 48.27% |
Operating Margin | 25.67% |
Pretax Margin | 35.46% |
Profit Margin | 29.41% |
EBITDA Margin | 29.74% |
EBIT Margin | 25.67% |
FCF Margin | 15.03% |
Dividends & Yields
This stock pays an annual dividend of 11.00, which amounts to a dividend yield of 4.89%.
Dividend Per Share | 11.00 |
Dividend Yield | 4.89% |
Dividend Growth (YoY) | 5.00% |
Years of Dividend Growth | 6 |
Payout Ratio | 45.63% |
Buyback Yield | n/a |
Shareholder Yield | 4.89% |
Earnings Yield | 10.15% |
FCF Yield | 5.19% |
Stock Splits
The last stock split was on November 23, 2020. It was a forward split with a ratio of 1.05.
Last Split Date | Nov 23, 2020 |
Split Type | Forward |
Split Ratio | 1.05 |
Scores
Square Pharmaceuticals PLC. has an Altman Z-Score of 20.38.
Altman Z-Score | 20.38 |
Piotroski F-Score | n/a |